Excessive bleeding during and after cardiac surgery is annoying, time-consuming and risky. Delayed sternal closure, increased blood transfusion requirements and increased possibility of re-operation are some of these risks. Each of these events has been associated with an increased risk of death after cardiac surgery [1] [2] [3] . In one study involving 11,963 coronary artery bypass graft (CABG) patients 1 , of whom 49% received red cell transfusion, transfusion was associated with significant increases in mortality (odds ratio [OR] 1.77 (95% confidence interval [CI] 1.67 to 1.87)), renal failure (OR 2.06 (95% CI 1.87 to 2.270)) and neurologic events (OR 1.37 (95% CI 1.30 to 1.44)). It is for these reasons that antifibrinolytic drugs such as tranexamic acid (TxA) and aminocaproic acid (EACA) are almost universally used in contemporary cardiac surgical practice.
Aspirin and other antiplatelet drugs are used commonly in cardiac surgical patients, and it has been a traditional practice to stop these at least five days before elective surgery. However, there are some compelling reasons to question the routine stopping of aspirin in these circumstances. Although preoperative aspirin may increase bleeding, it may also reduce myocardial infarction (MI) and other complications, including death. The antifibrinolytic drugs reduce excessive bleeding and may also have other benefits, but there is a possibility that they may increase thrombotic risks such as MI, stroke, pulmonary embolism and renal failure.
Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS; see www.atacas.org.au) is a factorial trial testing two hypotheses: 1) does aspirin given immediately before surgery reduce thrombotic complications after CABG without an increase in serious bleeding complications, and 2) does antifibrinolytic therapy with TxA reduce bleeding complications without an increase in thrombotic complications 4 . The primary endpoint of the trial is a composite of 30-day mortality or major thrombotic morbidity. We are also comparing rates of blood transfusion, re-operation, respiratory failure, serious wound infection and prolonged hospitalisation. The sample size is 4600 patients (alpha 0.05, beta 0.10), designed to detect a 30% or greater relative risk (RR) reduction in major complications or death. The aspirin analysis is due to report in 2014, and TxA is due in late 2015.
There have been ongoing concerns about antifibrinolytic therapy in CABG surgery, and aprotinin in particular. In 2007 there seemed to be mounting evidence suggesting that aprotinin could be associated with increased risks of renal failure, stroke and death after cardiac surgery 5, 6 . Although there were many criticisms of these studies 7, 8 , such a view was strengthened following publication of the Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study in 2009 9 . BART was a Canadian multicentre randomised trial comparing aprotinin, TxA and EACA in 2331 high-risk cardiac surgical patients. The primary outcome of the study was massive postoperative bleeding, for which aprotinin was found to provide a reduction in bleeding risk when compared with the lysine analogues, RR 0.79 (95% CI 0.59 to 1.05), but this was of borderline statistical significance. They also found that mortality was marginally higher in the aprotinin group, RR 1.53 (95% CI 1.06 to 2.22). The authors concluded that the risks of aprotinin outweighed the benefits and this, therefore, should preclude its use in high-risk cardiac surgery. Aprotinin was subsequently removed from the market by the manufacturers, and most cardiac surgical centres then converted to the use of one of the lysine analogues to provide antifibrinolytic therapy. This change in practice may have led to an increase in excessive bleeding in cardiac surgery 10, 11 .
Caution is needed when interpreting the results of the BART trial. Both the primary endpoint (major bleeding) and one of the secondary endpoints (mortality) were of borderline statistical significance. The primary endpoint was major haemorrhage, and there appeared to be a clinically important reduction of this when aprotinin was used. Aprotinin did not significantly increase the risk of renal failure or the need for postoperative renal replacement despite an increase in the proportion of patients who had a doubling of serum creatinine levels. Mortality was a secondary endpoint of the trial, and it may have been a spurious finding [12] [13] [14] . Given that meta-analyses of randomised trials had not previously identified an Anaesth Intensive Care 2014; 42: 293-297 Editorial Antifibrinolytics, aspirin and cardiac surgery: evidence, guidelines and implications for current research adverse mortality risk with aprotinin 15, 16 , the likelihood that this is a true effect is diminished. Furthermore, the trial had been stopped early, a practice that limits interpretation of the study findings, including an increased possibility of a type I error; that is, a false conclusion of a true difference between groups 17,18 .
Henry et al 19 has done an updated meta-analysis that included the BART data. They identified 49 trials involving 7439 participants. The summary RR for death with aprotinin versus placebo was 0.93 (95% CI 0.69 to 1.25). In the 19 trials that included TxA, the RR was 0.55 (95% CI 0.24 to 1.25). Therefore, neither was statistically significant. They found no difference in the risk of MI with the use of aprotinin compared with the lysine analogues in either direct or indirect analyses. For MI, the RR for TxA versus placebo (1732 participants) was 0.86 (95% CI 0.43 to 1.75). There was no difference in the risk of MI with the use of aprotinin or TxA (RR 1.0 (95% CI 0.71 to 1.43)). Therefore, this meta-analysis provides no evidence that aprotinin increases the risk of death.
In 2011, an update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines included two relevant recommendations 20 : 1) lysine analogues (EACA and TxA) reduce total blood loss and decrease the number of patients who require blood transfusion during cardiac procedures and are indicated for blood conservation (a Class 1a recommendation), and 2) aprotinin, in high (six million kallikrein inhibitor units) and low doses (one million kallikrein inhibitor units), reduces the number of adult patients requiring blood transfusion, total blood loss and re-exploration in patients undergoing cardiac surgery but is not indicated for routine blood conservation because the risks outweigh the benefits (Class 111a recommendation). High-dose aprotinin was not recommended (Class 111a), citing the BART trial.
Recent public statements by both Health Canada 21 and the European Medicines Agency 22 cast doubt about the conclusions of the BART trial, and both agencies have subsequently approved a resumption of the marketing of aprotinin for use in high-risk cardiac surgery. Of course, this may or may not assuage clinicians managing cardiac surgical patients, given that the lysine analogues seem to be sufficiently effective at reducing bleeding complications in most circumstances. But both TxA and EACA may have problems of their own.
Lysine analogue antifibrinolytics
Ngaage et al 11 undertook a meta-analysis to examine the efficacy and safety of TxA, comparing it both with placebo and head-to-head with aprotinin. They included 25 randomised trials (total n=5411) and four matched studies (total n=5977). When compared with placebo, TxA was associated with a lower mean difference in blood loss of around 300 ml and a near-halving in the rates of re-operation and blood transfusion (both P <0.05). However, TxA was associated with a non-significant increased risk of postoperative neurological events. There have been several case series highlighting risks of seizures with TxA 23-27 , as well as a possible prothrombotic effect from both TxA and EACA that may increase the risk of stroke 28, 29 . Given that thrombin generation continues after cardiac surgery 30 , it is at least conceivable that antifibrinolytic drugs may exacerbate a prothrombotic state.
Although (possibly) unrelated, recombinant factor VIIa (NovoSeven ® ; Novo Nordisk Inc., Plainsboro, NJ, USA) appears to increase the risk of stroke and other thromboembolic events. This potent procoagulant has, on occasion, been used to manage uncontrolled bleeding in cardiac surgery. A meta-analysis of six clinical studies (n=470) identified a near four-fold increased risk of stroke, OR 3.7 (95% CI 1.1 to 12), P=0.03 31 . While antifibrinolytics act via different mechanisms to that of factor VIIa, it highlights the possible prothrombotic effects of any drug used to control excessive bleeding in cardiac surgery.
Post-cardiac surgery seizures are associated with very poor outcomes [23] [24] [25] [26] [27] , including death. Kalavroutis et al 32 identified a significant increase in the incidence of early postoperative seizures, doubling to around 2.0% (P <0.0001), following the switch from aprotinin to TxA antifibrinolytic therapy in their institution following publication of the BART trial. Independent predictors of seizures included older age, open heart procedure (OR 12.0, P <0.001), renal failure, peripheral vascular disease and a total TxA dose of 100 mg/kg or more (OR 2.6, P <0.001). The risk of seizures was related to the dose of TxA, but there could be residual confounding if higher doses were used in more complex surgeries. Interestingly, postoperative chest tube drainage and blood product use were similar between patients receiving lowdose and high-dose TxA. In another study 27 , in which seizures occurred in 56 patients from a cohort of 5958 cardiac surgical cases (incidence 0.94%), TxA was also associated with a greatly increased risk of seizures, OR 7.4 (95% CI 2.8 to 19.3), P <0.001. Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3.2 versus 19.6%), increased intensive care unit stay (1.0 versus 4.7 days) and increased intensive care unit mortality (1.4 versus 9.7%), all P <0.01.
Given that higher doses (>50 mg/kg) of TxA add risk but without a measurable additional benefit in reduced bleeding 32 , it is now recommended that the dose of TxA be limited to 30 to 50 mg/kg in cardiac surgery. The ATACAS trial has reduced the administered dose of TxA from 100 mg/kg to 50 mg/kg, providing an opportunity to explore a dose effect.
Two mechanisms have been proposed to explain why TxA can induce seizures. Firstly, TxA may be prothrombotic and/or induce vasospasm, leading to cerebral ischaemia 34, 35 . Secondly, there is good evidence from the neurosurgical literature that TxA is a competitive antagonist at the otherwise inhibitory gamma-aminobutyric acid receptor 36, 37 . The latter explanation has been challenged because the dose of TxA used in cardiac surgery is unlikely to achieve the blood levels required to induce seizures 38 . This, therefore, once again raises a concern regarding a prothrombotic effect of TxA.
The lysine analogue antifibrinolytic drugs are used near universally and are inexpensive, yet we do not know whether or not they increase the risk of thrombotic complications in CABG surgery. The benefits of any reduction in bleeding, and possibly blood transfusion, achieved by TxA should not be outweighed by a higher rate of MI, stroke and death before TxA can be considered as a routine therapy during CABG and other open heart surgery.
Aspirin and CABG surgery
Aspirin is known to reduce thrombotic events in both non-surgical and surgical settings 39 , but aspirin has also been associated with excessive bleeding during and after cardiac surgery 40, 41 . Troublesome bleeding increases the need for blood transfusion and can delay chest closure and completion of surgery, as well as increase the risk of cardiac tamponade and re-operation for bleeding [1] [2] [3] . Those of us who work in the operating theatre tend to worry most about bleeding risks, and so it is no wonder that it has been traditional practice to stop aspirin before elective cardiac surgery. Cardiac surgery has a high bleeding risk, but there is also concern for MI, stroke and other thrombotic complications, so the risks and benefits for patients undergoing CABG surgery are unclear.
A small trial evaluating the continuation of aspirin therapy in patients with cardiovascular disease cotreated with a proton pump inhibitor after endoscopic control of ulcer bleeding 42 found a non-significant higher rate of recurrent ulcer bleeding within 30 days in the aspirin group (10.3%) compared with placebo (5.4%) (absolute risk difference 4.9% (95% CI -3.6 to 13.%)). Interestingly, patients who received aspirin had lower all-cause mortality than placebo patients (1.3 versus 12.9%; difference, 11.6% (95% CI 3.7 to 19.5%)). It may be that bleeding complications are outweighed by the antithrombotic benefits of aspirin.
Earlier studies may no longer be relevant because of changes in perfusion technologies and use of antifibrinolytic therapy. A recent propensity scoreadjusted analysis of 4256 cardiac surgical patients 43 comparing those taking (n=1923) or not taking (n=945) aspirin within five days of surgery found that aspirin patients had significantly reduced risk of 30-day mortality (3.5 versus 6.5%, OR 0.61 (95% CI 0.39 to 0.96, P=0.031)), postoperative renal failure (3.7 versus 7.1% (OR 0.38 (95% CI 0.25 to 0.58), P <0.001)), dialysis (1.9 versus 3.6%, OR 0.44 (95% CI 0.25 to 0.58, P <0.001)) and intensive care unit stay (P <0.001).
Recent guidelines from a variety of professional bodies have moved towards supporting the continuation of aspirin before elective CABG surgery [44] [45] [46] . The American College of Chest Physicians acknowledges the uncertainty in the relative risks and benefits of perioperative aspirin continuation and suggests that "clinicians may individualize patient management; for example, it may be reasonable to stop aspirin in patients with stable coronary artery disease who require CABG". Importantly, it stresses that additional research is necessary in order to provide more definitive guidelines.
A recent randomised trial from Poland reported on a comparison between aspirin and placebo in 793 elective CABG patients 47 . Aspirin patients had a higher rate of major bleeding (>750 ml) in the first 12 hours after surgery (OR 1.81 (95% CI 1.25 to 2.63)). Interestingly, however, aspirin-treated patients had a decreased risk of non-fatal coronary events (MI or repeat revascularisation) (hazard ratio 0.58 (95% CI 0.33 to 0.99)) and a possibly reduced risk of any major cardiac event (cardiovascular death, MI or repeat revascularisation) (hazard ratio 0.65 (95% CI 0.41 to 1.03)) out to three years after surgery. These data offer support for the rationale of the ATACAS trial 4 but, given the "positive" findings were based on a post hoc secondary endpoint, require confirmation.
In view of the importance of both thrombotic and bleeding complications, and the ongoing uncertainty as to the potential benefits and risks of both aspirin and antifibrinolytic therapy, a large trial in CABG surgery needs to be done in order to demonstrate whether the benefits of aspirin and TxA outweigh their risks. These are the aims of the ATACAS trial 4 . Only large randomised trials can provide the strong evidence needed to change practice [48] [49] [50] .
